Citations

Mayo Clinic

Showing 10 of 108599 citations.

Bortezomib induces oxidative stress and apoptosis that are synergistically enhanced by a Bcl-2 inhibitor in human pancreatic cancer cells
Freeburg, E. N., Huang, Der‐Yi, Yeung, Bryan K. S. , Sinicrope, Frank A.

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 3161-3161

10.1200/jco.2005.23.16_suppl.3161 Get It

A phase I dose-escalation and pharmacokinetic (PK) study of a novel multiple-targeted receptor tyrosine kinase (RTK) inhibitor, XL647, in patients with advanced solid malignancies
Wakelee, Heather A. , Adjei, Alex A. , Halsey, Joanne, Hanson, L., Hutchison, S , Piens, Jill, Lacy, Steven , Šikić, Branimir I. , Keer, Harold N , Reid, Joel M.

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 3142-3142

10.1200/jco.2005.23.16_suppl.3142 Get It

Pharmacokinetics (PK) and pharmacodynamics (PD) of PD 0325901, a second generation MEK inhibitor after multiple oral doses of PD 0325901 to advanced cancer patients
Menon, Sujatha, Whitfield, Lloyd R., Sadis, Seth, Leopold, Judith, LoRusso, Patricia , Krishnamurthi, Smitha , Rinehart, John, Nabell, Lisle, Croghan, Gary A., Meyer, Mark B.

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 3066-3066

10.1200/jco.2005.23.16_suppl.3066 Get It

Immunotherapy of malignant melanoma using a dendritic cell-amplified tumor RNA vaccine: A phase I study
Greiner, Carl, Maas, Mary, Butler, Greg W., Bulur, Peggy A. , Suman, V., Allred, Jacob B., Vuk‐Pavlović, Stanimir , Dietz, Allan B. , Markovic, Svetomir N.

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 2597-2597

10.1200/jco.2005.23.16_suppl.2597 Get It

N997D: Pilot trial of CPT11 during RT followed by CPT11 and BCNU in newly diagnosed glioblastoma (GBM) patients: A North Central Cancer Group (NCCTG) study
Jaeckle, Kurt A. , Schomberg, Paula J., Uhm, Joon H. , Schiethauer, B., Felton, Sally, Brown, Paul D. , Jan, B Z M Mubarak, Ballman, Karla V. , Giannini, Caterina

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 1514-1514

10.1200/jco.2005.23.16_suppl.1514 Get It

N997B: Phase II trial of CCI-779 in recurrent glioblastoma multiforme (GBM): Updated results and correlative laboratory analysis
Buckner, Jan C. , Kreisberg, Jeffrey I., Peralba, Josep Maria, Jenkins, Robert B. , Walsh, Daniel J. , Galanis, Evanthia , Maurer, Matthew J. , Hidalgo, Manuel , Walsh, D. J.

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 1505-1505

10.1200/jco.2005.23.16_suppl.1505 Get It

A phase III, intergroup, randomized, double-blind, chemoprevention trial of selenium (Se) supplementation in resected stage I non-small cell lung cancer (NSCLC).
Karp, Daniel D. , Wright, Gavin, Johnson, D. H., Johnston, M. R., Goodman, Gary E. , Clamon, G. H., Okawara, G. S., Marks, R., Ruckdeschel, John C. , Lee, S. J., Wright, G. L. Shaw

Journal of Clinical Oncology | February 23, 2017 | Volume: 28 | Issue: 18_suppl | Pages: CRA7004-CRA7004

10.1200/jco.2010.28.18_suppl.cra7004 Get It

CRA7004 Background: Selenium was reported to have possible lung cancer chemopreventive benefits based on a large skin cancer trial secondary observation. (JAMA 1996; 276: 1957-1963). Since that time, research continued to suggest that Se could decrease risk of second primary tumor (SPT) in persons with resected NSCLC. In 2007, a publication from another group suggested an increased association of Se with type 2 diabetes (Annals Int Med 147:217-223). Methods: From Oct 2000-Nov 2009, 6 groups, led by ECOG, carried out a double blind, placebo controlled trial using selenized yeast 200 micrograms daily in a 2:1 randomization vs. placebo for 48 mo in completely resected stage I NSCLC. Participation was 6–36 mo post-op and required a negative mediastinal node biopsy, no excessive vitamin intake, normal liver function, a negative chest x-ray, and no other evidence of recurrence. Planned size of 1,960 participants had been designed to detect a 40% decrease in SPTs with 80% power. Methylation studies of sputum and blood (S. Belinsky) add important biologic correlates to this project. Results: Interim analysis occurred in Oct 2009 after 1,561/1,772 pts reached step 2 (completion of the 4 week (step 1) run-in period requiring at least 75% of the study drug to be taken). Endpoints included SPTs, recurrence, and toxicity. A total of 216 SPTs developed of which 84 (38.9%) were lung cancer. SPT (lung/overall) incidence was 1.36/3.66 per 100 person yrs for placebo vs. 1.91/4.11 for Se (p=.150). 5 yr progression free survival was 78% for placebo vs. 72% for Se. Study was stopped according to futility analysis. Grade 1 or 2 toxicity occurred in 38% of placebo and 39% Se. Grade 3 toxicity was 3% placebo vs. <1% Se. Compliance was excellent (>95% at 2 yrs). Conclusions: No increase in diabetes mellitus or skin cancer was detected. Se was safe but conferred no benefit over placebo. Methylation studies are continuing. [Table: see text]
In Memoriam: Charles G. Moertel
O’Connell, Michael J.

Journal of Clinical Oncology | February 23, 2017 | Volume: 12 | Issue: 11 | Pages: 2246-2247

10.1200/jco.1994.12.11.2246 Get It

Management of Weight Gain in Midlife Women: Hormone Therapy and Beyond
Kapoor, Ekta , Files, Julia A. , Faubion, Stephanie S.

Journal of Women's Health | February 23, 2017 | Volume: 26 | Issue: 4 | Pages: 396-398

10.1089/jwh.2017.6324 | PMID 28410015 Get It

A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR‐CD) for untreated low‐grade non‐Hodgkin lymphoma requiring therapy
Rosenthal, Allison , Dueck, Amylou C. , Ansell, Stephen M. , Gano, Katherine, Conley, Christopher J. , Nowakowski, Grzegorz S. , Camoriano, John , Leis, José F., Stewart, A. Keith , Inwards, David J. , Dingli, David , Kumar, Shaji , Noël, Pierre, Porrata, Luis F. , Russell, Stephen J. , Kapoor, Prashant , Tiedemann, Rodger E. , Reeder, Craig B. , Conley, Christopher , Mikhael, Joseph R., Inwards, David, Porrata, Luis, Russell, Stephen, Colgan, Joseph, Witzig, T.E. , Reeder, Craig, Dueck, A. C. , Rosenthal, Allison , Mıkhael, Joseph , Gertz, Morie A. , Colgan, Joseph P. , Fonseca, Rafaël , Habermann, Thomas M. , Buadi, Francis K. , Leung, Nelson , Witzig, Thomas E. , Russell, Stephen J , Dingli, David

American Journal of Hematology | February 23, 2017 | Volume: 92 | Issue: 5 | Pages: 467-472

10.1002/ajh.24693 | PMID 28230270 Get It

AbstractPatients with indolent non‐Hodgkin lymphoma (NHL) have multiple treatment options yet there is no consensus as to the best initial therapy. Lenalidomide, an immunomodulatory agent, has single agent activity in relapsed lymphoma. This trial was conducted to assess feasibility, efficacy, and safety of adding lenalidomide to rituximab, cyclophosphamide, and dexamethasone (LR‐CD) in untreated indolent NHL patients requiring therapy. This was a single institution phase II trial. Treatment consisted of IV rituximab 375 mg/m2 day 1; oral lenalidomide 20 mg days 1–21; cyclophosphamide 250 mg/m2 days 1, 8, and 15; and dexamethasone 40 mg days 1, 8, 15, and 22 of a 28‐day cycle. Treatment continued 2 cycles beyond best response for a maximum of 12 cycles without rituximab maintenance. Thirty‐three patients were treated. Median age was 68 (43–83 years). 39% had stage IV disease. Histologic subtypes included 8 follicular lymphoma (FL), 7 marginal zone lymphoma (MZL) (1 splenic, 2 extranodal, and 4 nodal), 15 Waldenström's macroglobulinemia (WM), 1 lymphoplasmacytic lymphoma, 1 small lymphocytic lymphoma, and 1 low‐grade B‐cell lymphoma with plasmacytic differentiation (unable to be classified better as MZL or LPL). Hematologic toxicity was the most common adverse event. Median time of follow‐up was 23.4 months (range 1.8–50.9). The overall response rate was 87.9%, with 30.3% complete response. The median duration of response was 38.7 months. The median progression free survival was 39.7 months, while median overall survival (OS) has not yet been reached. Lenalidomide can be safely added to a simple regimen of rituximab, oral cyclophosphamide, and dexamethasone and is an effective combination as initial therapy for low‐grade B‐cell NHL.